Imcyse raises €21M and opens its capital to its new American partner, Pfizer. Very good news for the Liège-based biotech company Imcyse. Indeed, the biotech has developed an active immunotherapy technology that allows to tackle autoimmune diseases such as multiple sclerosis, type 1 diabetes or rheumatoid arthritis. A licensing agreement has just been signed with[…]